October 2026 Random Ramblings
October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.
October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.
@SmallCapVal Was excited to see an insider purchase at $CME filed yesterday but it turned out to be a dividend reinvestment as most of the purchases at $CME tend to be. https://t.co/E7mlsW02I3
Paramount's $52bn $WBD debt package is FINALLY in the market. Here's the package: $32bn of IG-rated 1L bonds, the 5th-largest US high-grade sale EVER. Plus $7.5bn of loans and $12.4bn of 2L HY bonds. Paramount's existing unsecured bonds? Primed. Back of the line. Good luck and thanks for playing. Where in the cap stack are you playing? $PSKY $PARA
@accrued_int Yes indeed! Tons of buying In $DKS since August. Retail has generally been a difficult sector for me and so I am approaching this cautiously. https://t.co/sQw6OWE2zl
Selling low vol international stuff and buying risk and rate exposure today (with some hedging using $ANGL, $SMH and $QQQ). Purely a sentiment and positioning thesis. Historically I've been too cautious in these sorts of dislocations so im trying something new.
Fair Isaac $FICO is getting killed today. Looks absolutely hammered. Should deep value guys be buying this today? What’s the worst case scenario here? https://t.co/Ag4mL0lbrS
Is $70B ARR for OpenAI ahead of expectations? I dunno ask $ORCL https://t.co/tNjIjh8Ya1 https://t.co/WBWM3ghxSm
72% drawdown on $FICO https://t.co/PUmZEyBrqV
First Tracks Biotherapeutics’ ANB033 posted stronger Phase 1b celiac efficacy than Teva’s IL-15 inhibitor, with $168 million funding…
Howmet Aerospace is framed as a beneficiary of turbine and aircraft-engine demand, while J.B.
Palantir is cut to Hold after a 35% multiple-driven rally, while C3.ai is rated Sell on stalled revenue, expensive valuation and weak…
Lennar cut build times to 116 days and adopted an asset-light land model, while gross margin fell to 15.8% from 27.5% as land costs rose.
Lennar grew from a Miami builder into one of America’s two largest homebuilders, controlling land largely through options and land banks…
Lennar’s second audio program examines the homebuilder’s business for professional investors and housing analysts.
Eaton’s backlog, data-center, grid and aerospace demand, plus a 450–500 bp H2 2026 Electrical Americas margin recovery, support the growth…
Asian insider buying rose 19% to US$2.4 billion across 930 September transactions, led by Grab CEO Anthony Tan’s US$30 million purchase…
ASML’s strong quarterly results failed to prevent a selloff, as AI investors focused on scarcity fears facing chip-equipment makers…
Corning’s NVIDIA-backed 10x fiber expansion, enterprise connector demand and carrier capacity plans frame its optical communications…
WDC · long Western Digital, a hard-disk manufacturer, is pitched as a long after significant share-price moves deter investors.
Verisure’s 6.38 million monitored-alarm subscribers generate 90% recurring revenue, while its disclosed acquisition costs and 6%-8% churn…
BridgeBio Pharma reported Q2 revenue of $243.7 million and has three Priority Review NDAs, while $1 billion in convertible preferred…
Everpure and DigitalOcean face rising expectations as their stock prices shape Monday’s views.
Vicor uses ITC exclusion-order cases to license power-module patents, with published royalty multipliers rising from 1.0x before filing to…
Rubrik posted 38% Q2 revenue growth to $427.3 million, but Cloud ARR growth slowed to 39% and its enterprise value reached 15.7 times…
Nebius’s 1 GW annual active-capacity target from 2027 is realistic, according to a former product manager, with greenfield data centers…
Dell booked $131.7B of AI server orders in four quarters and held a $95B backlog as enterprise AI demand accelerates.
Jenga Global Master Fund returned 8.10% in Q3 2026, added Adobe and Mexican airports, and later initiated S&P Global.
Liquidia’s Yutrepia sales reached $170.4 million in Q2 2026, while a patent ruling threatens its PH-ILD label but leaves PAH sales and a…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.